Skip to main content
. 2019 Nov 3;2019:7536803. doi: 10.1155/2019/7536803

Figure 7.

Figure 7

Blocking PPARα/NRF2 signaling counteracts zileuton's effect on vitro. (a–c) Cells were treated with NRF2 siRNA for 8 h and then treated with PE (50 μM) and zileuton (100 μM) for 24 h. (d–g) Cells were treated with PE (50 μM), zileuton (100 μM), and GW6471 (10 μM) for 24 h. (a) Expression of Nrf2 in cells (n = 6, ∗P < 0.05 vs. the control group). (b, e) α-Actinin staining (n = 6) and quantification results in H9c2 cells. (c, f) Transcription levels of hypertrophic markers (n = 6). (d, g) ROS levels and activities of SOD, Gpx, and NADPH oxidase (n = 6). ∗P < 0.05 vs. the control group; #P < 0.05 vs. the PE group.